{"id":751275,"date":"2023-04-26T07:18:30","date_gmt":"2023-04-26T11:18:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/"},"modified":"2023-04-26T07:18:30","modified_gmt":"2023-04-26T11:18:30","slug":"eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/","title":{"rendered":"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023"},"content":{"rendered":"
\n

WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 3, 2023 to report its first quarter 2023 financial results and highlight recent corporate developments.<\/p>\n

To access the live conference call, please register using the audio conference link: https:\/\/register.vevent.com\/register\/BI90ffc1666dc94fd1b3705e1b5ec9157d<\/a>. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com<\/a>. A webcast replay will also be available on the corporate website at the conclusion of the call.<\/p>\n

\n About EyePoint Pharmaceuticals
<\/strong>EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert\u00ae technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been safely administered to thousands of patients’ eyes across four U.S. FDA approved products, including YUTIQ\u00ae for the treatment of posterior segment uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.<\/p>\n

\n Investors:<\/strong>
\n
Anne Marie Fields
Stern IR
Direct: 332-213-1956
annemarie.fields@sternir.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 3, 2023 to report its first quarter 2023 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https:\/\/register.vevent.com\/register\/BI90ffc1666dc94fd1b3705e1b5ec9157d. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call. About EyePoint PharmaceuticalsEyePoint Pharmaceuticals (Nasdaq: … <\/p>\n

Continue reading “EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751275","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 3, 2023 to report its first quarter 2023 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https:\/\/register.vevent.com\/register\/BI90ffc1666dc94fd1b3705e1b5ec9157d. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call. About EyePoint PharmaceuticalsEyePoint Pharmaceuticals (Nasdaq: … Continue reading "EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T11:18:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDM3OSM1NTU0MDQ4IzIwMDU4MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023\",\"datePublished\":\"2023-04-26T11:18:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/\"},\"wordCount\":256,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDM3OSM1NTU0MDQ4IzIwMDU4MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/\",\"name\":\"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDM3OSM1NTU0MDQ4IzIwMDU4MTc=\",\"datePublished\":\"2023-04-26T11:18:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDM3OSM1NTU0MDQ4IzIwMDU4MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDM3OSM1NTU0MDQ4IzIwMDU4MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/","og_locale":"en_US","og_type":"article","og_title":"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk","og_description":"WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 3, 2023 to report its first quarter 2023 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https:\/\/register.vevent.com\/register\/BI90ffc1666dc94fd1b3705e1b5ec9157d. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call. About EyePoint PharmaceuticalsEyePoint Pharmaceuticals (Nasdaq: … Continue reading \"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T11:18:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDM3OSM1NTU0MDQ4IzIwMDU4MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023","datePublished":"2023-04-26T11:18:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/"},"wordCount":256,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDM3OSM1NTU0MDQ4IzIwMDU4MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/","name":"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDM3OSM1NTU0MDQ4IzIwMDU4MTc=","datePublished":"2023-04-26T11:18:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDM3OSM1NTU0MDQ4IzIwMDU4MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDM3OSM1NTU0MDQ4IzIwMDU4MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-to-report-first-quarter-2023-financial-results-on-may-3-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Results on May 3, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751275"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751275\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}